Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials

Ahmadaye Ibrahim Khalil, Li Zhang, Richard Muwonge, Catherine Sauvaget, Partha Basu
doi: https://doi.org/10.1101/2022.11.11.22282221

Article Information

doi 
https://doi.org/10.1101/2022.11.11.22282221
History 
  • November 15, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Ahmadaye Ibrahim Khalila,*,
  2. Li Zhanga,*,
  3. Richard Muwongea,
  4. Catherine Sauvageta and
  5. Partha Basua,#
  1. aEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
  1. ↵#Author for correspondence:
    Dr Partha Basu, Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France, E-mail: basup{at}iarc.who.int; Tel: +33-472738167; fax: +33-472738518

  1. ↵* Contributed equally

Back to top
Posted November 15, 2022.
Download PDF
Data/Code
Email
Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials
Ahmadaye Ibrahim Khalil, Li Zhang, Richard Muwonge, Catherine Sauvaget, Partha Basu
medRxiv 2022.11.11.22282221; doi: https://doi.org/10.1101/2022.11.11.22282221
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area